Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Study design in osteoporosis: a European perspective.

J A Kanis1, J M Alexandre, H G Bone

  • 1WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom. W.J.Pointefract@sheffield.ac.uk

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|June 24, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2020
Same author

[S3 guideline sepsis-prevention, diagnosis, treatment, and aftercare : Summary of the strong recommendations].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2020
Same author

Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2018
Same author

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017

New osteoporosis treatments are available, but placebo-controlled trials remain crucial for efficacy testing. Superiority or equivalence studies are often impractical due to large sample sizes and unclear results.

Area of Science:

  • Bone health research
  • Clinical trial design
  • Pharmacological efficacy studies

Background:

  • Effective osteoporosis treatments exist, challenging traditional trial designs.
  • Current recommendations favor superiority, equivalence, or non-inferiority trials over placebo controls.
  • Large sample sizes and increased fracture burden are concerns in new trial designs.

Purpose of the Study:

  • To evaluate the appropriateness of placebo-controlled trials for new osteoporosis agents.
  • To discuss the limitations of superiority, equivalence, and non-inferiority studies in osteoporosis research.
  • To address the ongoing need for placebo-controlled studies, potentially with adjusted durations.

Main Methods:

  • Critical review of current clinical trial methodologies in osteoporosis.
Keywords:
Biomedical and Behavioral Research

Related Experiment Videos

  • Analysis of the statistical and practical challenges of equivalence and non-inferiority trials.
  • Examination of regulatory requirements for osteoporosis drug efficacy studies.

    • Main Results:

    • Superiority, equivalence, and non-inferiority trials present significant challenges in osteoporosis, including large sample sizes and interpretational difficulties.
    • Equivalence studies are particularly problematic due to high variance in active comparator effects.
    • Placebo-controlled trials, despite challenges, may still be necessary for regulatory approval.

    Conclusions:

    • Placebo-controlled trials remain relevant for osteoporosis drug efficacy assessment.
    • Alternative trial designs face substantial practical and statistical hurdles.
    • Regulatory agencies may still require placebo-controlled studies, possibly of shorter duration.